IMVT has 36-month beta value of 0.71. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IMVT is 61.87M, and currently, short sellers hold a 16.20% ratio of that float. The average trading volume of IMVT on July 24, 2024 was 1.15M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IMVT) stock’s latest price update
The stock price of Immunovant Inc (NASDAQ: IMVT) has dropped by -0.04 compared to previous close of 28.00. Despite this, the company has seen a fall of -9.48% in its stock price over the last five trading days. zacks.com reported 2024-05-30 that Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.
IMVT’s Market Performance
IMVT’s stock has fallen by -9.48% in the past week, with a monthly rise of 2.45% and a quarterly drop of -2.61%. The volatility ratio for the week is 5.33% while the volatility levels for the last 30 days are 4.73% for Immunovant Inc. The simple moving average for the past 20 days is -0.86% for IMVT’s stock, with a -16.43% simple moving average for the past 200 days.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Oppenheimer repeating the rating for IMVT by listing it as a “Outperform.” The predicted price for IMVT in the upcoming period, according to Oppenheimer is $50 based on the research report published on March 28, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see IMVT reach a price target of $50. The rating they have provided for IMVT stocks is “Buy” according to the report published on March 13th, 2024.
JP Morgan gave a rating of “Overweight” to IMVT, setting the target price at $51 in the report published on February 20th of the current year.
IMVT Trading at 0.11% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.59% of loss for the given period.
Volatility was left at 4.73%, however, over the last 30 days, the volatility rate increased by 5.33%, as shares surge +2.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.76% lower at present.
During the last 5 trading sessions, IMVT fell by -9.48%, which changed the moving average for the period of 200-days by -17.70% in comparison to the 20-day moving average, which settled at $28.26. In addition, Immunovant Inc saw -33.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from Salzmann Peter, who sale 8,685 shares at the price of $29.69 back on Jul 17 ’24. After this action, Salzmann Peter now owns 1,023,412 shares of Immunovant Inc, valued at $257,887 using the latest closing price.
Barnett Eva Renee, the Chief Financial Officer of Immunovant Inc, sale 3,123 shares at $29.69 during a trade that took place back on Jul 17 ’24, which means that Barnett Eva Renee is holding 347,544 shares at $92,733 based on the most recent closing price.
Stock Fundamentals for IMVT
The total capital return value is set at -0.43. Equity return is now at value -52.91, with -48.36 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -1552.37.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 2.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.70.
Conclusion
To put it simply, Immunovant Inc (IMVT) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
